KRRO — Korro Bio, Inc.

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 112
• Website: https://www.korrobio.com

Latest SEC filings for KRRO

• 8-K — 2026-10-05
• 8-K — 2026-08-19
• SCHEDULE 13G/A — 2026-08-14
• 8-K — 2026-08-06
• 10-Q — 2026-08-06
• 8-K — 2026-06-11
• 8-K — 2026-05-19
• SCHEDULE 13G/A — 2026-05-15
• 424B3 — 2026-05-12
• 10-Q — 2026-05-07

Latest KRRO news

• 2026-10-23 — Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains? (Zacks Investment Research)
• 2026-10-05 — Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 (globenewswire.com)

Abrir análisis completo

Educational tool only — not investment advice.